These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10191862)

  • 21. [Somadril will be recalled June 1, 2008].
    Bülow B; Bergman B
    Lakartidningen; 2008 Apr 2-8; 105(14):1031. PubMed ID: 18478757
    [No Abstract]   [Full Text] [Related]  

  • 22. The relief of muscle spasm and pain with chlormezanone and chlormezanone with aspirin: a blind, crossover study.
    Woolsey RM; Tureen LL; Murphy MQ
    Curr Ther Res Clin Exp; 1966 Feb; 8(2):52-5. PubMed ID: 4955381
    [No Abstract]   [Full Text] [Related]  

  • 23. Muscle relaxants in cerebral palsy: a comparative study. II. Chlorophenylmethylthiazanone sulfone (trancopal).
    STERLING HM
    Arch Phys Med Rehabil; 1960 Jun; 41():226-8. PubMed ID: 13834416
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacologic and toxicologic studies of two new centrally acting skeletal muscle relaxants, chlormethazanone and dichlormethazanone.
    GESLER RM; COULSTON F
    Toxicol Appl Pharmacol; 1959 Mar; 1(2):168-84. PubMed ID: 13635687
    [No Abstract]   [Full Text] [Related]  

  • 25. [Drug therapy of cerebral palsy with chlormethazanone].
    HANSEN E
    Ugeskr Laeger; 1961 Sep; 123():1353-4. PubMed ID: 13904411
    [No Abstract]   [Full Text] [Related]  

  • 26. [Important pharmaceutical-chemical characteristics of the central muscle relaxant chlormezanone].
    Seeling A; Oelschläger H; Rothley D
    Pharmazie; 2000 Apr; 55(4):293-6. PubMed ID: 10798243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fixed drug eruption due to chlormezanone.
    McFadden N
    Dermatologica; 1988; 176(2):106. PubMed ID: 2967209
    [No Abstract]   [Full Text] [Related]  

  • 28. [New findings on the synthesis of the centrally acting muscle relaxant chlormezanone and its resolution of a gram scale using a Chiralcel OD column].
    Oelschläger H; Wange J; Letsch J; Seeling A
    Pharmazie; 2003 Feb; 58(2):95-8. PubMed ID: 12641322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis associated with chlormezanone.
    Ohsawa T; Konishi K
    Drug Intell Clin Pharm; 1986 Jun; 20(6):506. PubMed ID: 3720548
    [No Abstract]   [Full Text] [Related]  

  • 30. Fixed drug eruption caused by chlormezanone.
    Mohamed KN
    Int J Dermatol; 1983 Nov; 22(9):548. PubMed ID: 6227574
    [No Abstract]   [Full Text] [Related]  

  • 31. The measurement of spasticity. Description of a method and evaluation of a druge: trancopal.
    TORRES F; SANDLER B; DE TORRES T
    Minn Med; 1960 Jan; 43():16-21. PubMed ID: 13838937
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of central muscle relaxants on single-dose pharmacokinetics of peroral paracetamol in man.
    Saano V; Elo HA; Paronen P
    Int J Clin Pharmacol Ther Toxicol; 1990 Jan; 28(1):39-45. PubMed ID: 2303311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fixed drug eruption caused by chlormezanone.
    Rademacher D; Gerhardt G; Brasch J
    Contact Dermatitis; 1995 Feb; 32(2):117-8. PubMed ID: 7758315
    [No Abstract]   [Full Text] [Related]  

  • 34. Investigations of interactions of chlormezanone racemate and its enantiomers on human keratinocytes and human leucoytes in vitro.
    Wollina U; Hipler UC; Seeling A; Oelschlager H
    Skin Pharmacol Physiol; 2005; 18(3):132-8. PubMed ID: 15897685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Centrally acting muscle relaxants and traffic hazards].
    Bramness JG; Skurtveit S; Grung M; Mørland J
    Tidsskr Nor Laegeforen; 2000 Jun; 120(17):1966-9. PubMed ID: 11008526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trancopal in the treatment of musculoskeletal conditions and symptoms of allergy: report on 1391 patients.
    COHEN AI
    Curr Ther Res Clin Exp; 1960 Aug; 2():374-8. PubMed ID: 13810913
    [No Abstract]   [Full Text] [Related]  

  • 37. Relative bioavailability of 3 different chlormezanone 200 mg preparations after single dose oral administration.
    Schütz H; Eichinger A; Nitsche V; Hofmann R
    Int J Clin Pharmacol Ther; 1997 Mar; 35(3):112-6. PubMed ID: 9089000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Fixed pigmented erythema caused by chlormezanone].
    el Sayed F; Bazex J; Cathala J; Viraben R; Bouissou X; Gorguet B
    Ann Dermatol Venereol; 1992; 119(9):671-2. PubMed ID: 1285595
    [No Abstract]   [Full Text] [Related]  

  • 39. [Use of a new muscle relaxant (Chlormezanone) in spasticity].
    NAUMANN B
    Sven Lakartidn; 1960 Nov; 57():3378-80 passim. PubMed ID: 13727979
    [No Abstract]   [Full Text] [Related]  

  • 40. [Results of electromyographic studies with central muscle relaxants--feasibility of objectivization and standardization].
    Ollinger H; Gruber J; Singer F
    EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb; 1985 Jun; 16(2):104-7. PubMed ID: 3930209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.